This bill proposes an amendment to the Code of West Virginia, specifically addressing Schedule I drugs under section 60A-2-204. The key insertion is the inclusion of crystalline polymorph psilocybin, which has received approval from both the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). By formally recognizing and regulating this specific form of psilocybin, the amendment aligns state law with federal regulations, reflecting the evolving legal landscape surrounding psilocybin and its potential therapeutic applications.

Additionally, the bill introduces provisions for synthetic cannabinoids and tryptamines, establishing a framework for the scheduling of crystalline polymorph psilocybin. It includes a comprehensive list of synthetic compounds classified as Cannabinoid receptor type 1 agonists, which are not federally approved or used in legitimate medical research. A significant insertion allows for the lawful prescription, distribution, and marketing of crystalline polymorph psilocybin, known as COMP360, contingent upon FDA approval and DEA scheduling. This change aims to enhance public health and safety by regulating emerging synthetic substances while facilitating the medical use of approved compounds.

Statutes affected:
Introduced Version: 60A-2-204